This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Overdose of calcium channel blocker

Authoring team

Calcium channel blocker (CCB) overdoses are associated with significant morbidity and mortality.

CCBs are classified into two main clinical categories based on their physiological effects:

  • dihydropyridines (eg, amlodipine, nifedipine, felodipine, nicardipine)
  • non-dihydropyridines (eg, verapamil and diltiazem)

Severe CCB toxicities may present with life-threatening bradycardia, hypotension, hyperglycemia, and renal insufficiency (1)

  • dihydropyridine toxicity, however, may present with reflex tachycardia instead of bradycardia
    • dihydropyridines have a greater affinity for peripheral vascular smooth muscle cells, while nondihydropyridines have a greater affinity for cardiomyocytes

A review found that verapamil and diltiazem are more toxic calcium channel blockers in overdose compared to dihydropyridines (2).

Reference:

  1. Alshaya OA et al. Calcium Channel Blocker Toxicity: A Practical Approach. J Multidiscip Healthc. 2022 Aug 30;15:1851-1862.
  2. Isbister GK, Jenkins S, Harris K, Downes MA, Isoardi KZ. Calcium channel blocker overdose: Not all the same toxicity. Br J Clin Pharmacol. 2024; 1-8.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.